Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) have earned an average rating of “Buy” from the nine ratings firms that are covering the company. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $12.88.
A number of equities research analysts have recently issued reports on FOLD shares. Zacks Investment Research lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 11th. Chardan Capital set a $15.00 price target on shares of Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, August 11th. Leerink Swann reiterated a “buy” rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a research note on Tuesday, November 8th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $15.00 price objective on shares of Amicus Therapeutics in a research note on Tuesday, November 8th.
Amicus Therapeutics (NASDAQ:FOLD) traded down 4.55% during mid-day trading on Friday, hitting $8.81. The stock had a trading volume of 1,385,083 shares. Amicus Therapeutics has a 52-week low of $4.98 and a 52-week high of $11.78. The stock’s market cap is $1.25 billion. The firm has a 50-day moving average of $7.76 and a 200-day moving average of $6.94.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The company earned $2.10 million during the quarter, compared to analyst estimates of $1.71 million. On average, analysts forecast that Amicus Therapeutics will post ($1.38) EPS for the current fiscal year.
In other news, CFO William D. Baird III sold 20,500 shares of the stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $8.00, for a total transaction of $164,000.00. Following the transaction, the chief financial officer now owns 56,450 shares in the company, valued at approximately $451,600. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Hung Do sold 25,000 shares of the stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $7.00, for a total transaction of $175,000.00. Following the transaction, the insider now owns 583,453 shares in the company, valued at approximately $4,084,171. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd acquired a new position in shares of Amicus Therapeutics during the second quarter valued at approximately $108,000. SG Americas Securities LLC acquired a new position in shares of Amicus Therapeutics during the third quarter valued at approximately $151,000. Principal Financial Group Inc. raised its position in shares of Amicus Therapeutics by 10.5% in the second quarter. Principal Financial Group Inc. now owns 22,411 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 2,122 shares during the period. BlackRock Inc. increased its stake in Amicus Therapeutics by 224.8% in the second quarter. BlackRock Inc. now owns 26,443 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 18,301 shares in the last quarter. Finally, Endurant Capital Management LP purchased a new stake in Amicus Therapeutics during the third quarter valued at about $317,000.